The Pyruvate Dehydrogenase Complex (PDC) is a critical mitochondrial multi-enzyme complex that serves as the metabolic bridge between glycolysis and the tricarboxylic acid (TCA) cycle by catalyzing the oxidative decarboxylation of pyruvate into acetyl-CoA. Comprising three core enzyme subunits—E1 (pyruvate dehydrogenase), E2 (dihydrolipoyl transacetylase), and E3 (dihydrolipoyl dehydrogenase)—the complex relies on a suite of essential cofactors, including thiamine pyrophosphate (TPP), lipoic acid, coenzyme A, FAD, and NAD+, to facilitate its catalytic activity. The functional output of PDC is tightly regulated by a phosphorylation-dephosphorylation cycle, where pyruvate dehydrogenase kinase (PDK) inactivates the complex and pyruvate dehydrogenase phosphatase (PDP) reactivates it, thereby modulating cellular energy flux in response to metabolic demands. Genetic mutations in PDC components, such as PDHA1 and PDHB, result in pyruvate dehydrogenase deficiency, a severe metabolic disorder characterized by lactic acidosis, neurodegeneration, and developmental delays, particularly affecting high-energy tissues like the brain and skeletal muscle. Conversely, dysregulated PDC expression has profound implications for disease pathogenesis; while overexpression can enhance acetyl-CoA supply for lipid synthesis and histone acetylation, it may also precipitate oxidative stress, whereas reduced activity leads to pyruvate accumulation and a shift toward lactate production. This metabolic flexibility is exploited in various pathologies, including diabetes and neurodegenerative diseases, and is central to the Warburg effect in cancer, where tumor cells often suppress PDC activity to sustain aerobic glycolysis. Consequently, understanding the intricate regulation and genetic variability of the PDC family offers significant insights for developing therapeutic strategies targeting metabolic disorders and oncological interventions.
Subcellular localization of PDC (and its protein):
Gene Ontology (GO) terms for PDC:
| Interacting Gene | Interaction | Source/Score |
| Disease | Score | NofPmids | NofSnps | Source |
| Retinitis Pigmentosa | 0.002909916 | 2 | 0 | BeFree_GAD |
| Blind Vision | 0.00272435 | 1 | 0 | LHGDN |
| Schizophrenia | 0.002367032 | 1 | 1 | GAD |
| Hypertensive disease | 0.001628651 | 6 | 1 | BeFree |
| Retinal Diseases | 0.000542884 | 2 | 0 | BeFree |
| Amyotrophic Lateral Sclerosis | 0.000542884 | 2 | 0 | BeFree |
| Polycythemia | 0.000542884 | 2 | 0 | BeFree |
| Dementia | 0.000542884 | 2 | 0 | BeFree |
| leukemia | 0.000542884 | 2 | 0 | BeFree |
| Primary biliary cirrhosis | 0.000542884 | 2 | 0 | BeFree |
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com